New STAIRWAY study data shows potential for extended durability with Roche's faricimab in neovascular age-related macular degeneration (nAMD)
October 29, 2018 02:00 ET
|
F. Hoffmann-La Roche Ltd
Faricimab - the first bispecific antibody designed for the eye - dosed every four months demonstrated sustained vision outcomes compared to monthly ranibizumab for people with nAMD [1] Further...
De nouvelles données de l'étude STAIRWAY montrent que le faricimab de Roche offre un potentiel de durabilité accrue dans le traitement de la dégénérescence maculaire néovasculaire liée à l'âge
October 29, 2018 02:00 ET
|
F. Hoffmann-La Roche Ltd
Le faricimab - le premier anticorps bispécifique conçu pour l'oeil - administré tous les quatre mois a démontré des résultats dans le maintien de la vision comparables au ranibizumab mensuel chez...
New STAIRWAY study data shows potential for extended durability with Roche's faricimab in neovascular age-related macular degeneration (nAMD)
October 29, 2018 02:00 ET
|
F. Hoffmann-La Roche Ltd
Faricimab - the first bispecific antibody designed for the eye - dosed every four months demonstrated sustained vision outcomes compared to monthly ranibizumab for people with nAMD [1] Further...
Roche announces FDA approval of Xofluza (baloxavir marboxil) for influenza
October 24, 2018 13:00 ET
|
F. Hoffmann-La Roche Ltd
First and only single-dose oral medicine approved to treat the flu Xofluza significantly reduced the duration of flu symptoms compared to placebo First novel proposed mechanism of action to...
Roche's Alecensa (alectinib) significantly reduced the risk of disease worsening or death as first-line treatment in Asian patients with ALK-positive advanced or metastatic non-small cell lung cancer
October 22, 2018 10:30 ET
|
F. Hoffmann-La Roche Ltd
Head-to-head phase III study of Alecensa versus crizotinib in Asian patient population showed a reduction in the risk of disease worsening or death by 78% Alecensa lowered the risk of tumour spread...
Roche's Alecensa (alectinib) significantly reduced the risk of disease worsening or death as first-line treatment in Asian patients with ALK-positive advanced or metastatic non-small cell lung cancer
October 22, 2018 10:30 ET
|
F. Hoffmann-La Roche Ltd
Head-to-head phase III study of Alecensa versus crizotinib in Asian patient population showed a reduction in the risk of disease worsening or death by 78% Alecensa lowered the risk of tumour...
Roche's Tecentriq plus chemotherapy (carboplatin and Abraxane) as an initial treatment helped people with advanced non-small cell lung cancer live significantly longer compared to chemotherapy alone
October 22, 2018 03:15 ET
|
F. Hoffmann-La Roche Ltd
The Phase III IMpower130 study investigating the Tecentriq plus chemotherapy combination demonstrated a significant overall survival (OS) and progression-free survival (PFS) benefit Data will...
Roche's investigational personalised medicine entrectinib shrank tumours in people with NTRK fusion-positive solid tumours
October 21, 2018 05:00 ET
|
F. Hoffmann-La Roche Ltd
Entrectinib showed response irrespective of tumour type or spread to the central nervous system (CNS) Data will be submitted to global regulatory authorities, including the US Food and Drug...
Roche's Tecentriq in combination with Abraxane improves outcomes as an initial treatment for people with PD-L1-positive metastatic triple-negative breast cancer
October 20, 2018 10:30 ET
|
F. Hoffmann-La Roche Ltd
Tecentriq combination first immunotherapy regimen to demonstrate positive Phase III results in breast cancer Tecentriq and nab-paclitaxel significantly reduced the risk of disease worsening or...